Financing supports first spinout of Orchard Ultrasound Innovation as MaxQ Medical advances its transurethral imaging and therapy system for BPH and prostate cancer

融资支持 Orchard Ultrasound Innovation 的首次分拆，与此同时 MaxQ Medical 正在推进其用于良性前列腺增生和前列腺癌的经尿道成像与治疗系统。

SUNNYVALE, Calif.

加利福尼亚州森尼韦尔

,

，

Aug. 20, 2026

2026年8月20日

/PRNewswire/ --

/美通社/ --

MaxQ Medical, Inc

MaxQ医疗公司

., a private health-tech company developing an all-in-one transurethral imaging and therapy system for prostate care, today announced the closing of a $31.5 million Series A financing. The round was led by Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures with strong participation from our existing investor, Hillside Capital.

., 一家致力于开发用于前列腺护理的一体化经尿道成像与治疗系统的私营健康科技公司，今日宣布完成3150万美元的A轮融资。本轮融资由Atlantic Blue Ventures、S3 Ventures和Olympus Innovation Ventures领投，现有投资者Hillside Capital也积极参与。

Funds will be used to grow the team and advance the company's clinical program..

资金将用于扩大团队规模并推进公司的临床项目。

'Men with prostate disease have had to choose between treatments that don't do enough and treatments that come with consequential tradeoffs and side-effects. The MaxQ system is designed to offer the durability of gold standard resective therapies with side-effects more comparable to tMIS solutions,' said Amir Tehrani, CEO of MaxQ Medical.  'I want to thank our investors for their support, our exceptional team for their dedication, and Amir Abolfathi, our executive chairman, co-leading this financing effort with me.

“患有前列腺疾病的男性不得不在疗效不足的治疗方案与伴随显著权衡和副作用的治疗方案之间做出选择。MaxQ系统旨在提供媲美金标准切除疗法的持久性，同时其副作用更类似于微创手术（tMIS）解决方案。”MaxQ Medical首席执行官阿米尔·泰赫拉尼表示。“我要感谢我们的投资者给予的支持，感谢我们卓越团队的奉献精神，并感谢我们的执行董事长阿米尔·阿博尔法蒂与我共同领导此次融资工作。”

This funding lets us continue the clinical evaluations already underway and move closer to giving physicians and their patients a better option.'.

这笔资金使我们能够继续开展正在进行的临床评估，并朝着为医生及其患者提供更优选择的目标更进一步。

MaxQ Medical is developing a platform technology that combines advanced imaging with tissue-selective therapy in a single transurethral procedure, giving urologists full visibility inside the prostate and the ability to treat what they see, without the anatomic limitations of approaches that work from outside of the prostate.

MaxQ Medical 正在开发一种平台技术，将先进成像与组织选择性疗法结合于单次经尿道手术中，使泌尿科医生能够全面清晰地观察前列腺内部，并对所见病灶进行治疗，而不受从前列腺外部进行操作的方法所存在的解剖学限制。

The design is intended to preserve the urethra and minimize side effects such as injury, swelling and bleeding, and impact on sexual functions which remain common concerns with current treatment options. The company's first indication is benign prostate hyperplasia (BPH), with plans to expand into focal therapy for prostate cancer and, longer term, into broader prostate diagnostics including biopsy and tumor mapping..

该设计旨在保护尿道，并最大限度地减少损伤、肿胀和出血等副作用，以及对性功能的影响，而这些正是当前治疗方案中普遍存在的担忧。公司的首个适应症为良性前列腺增生（BPH），并计划将业务扩展至前列腺癌的局灶性治疗，从长远来看，还将拓展至更广泛的前列腺诊断领域，包括活检和肿瘤 mapping。

'Our work in semiconductor ultrasound has spanned decades, and this is the first time we've taken that foundation and built a complete imaging and therapy system around it,' said Professor Pierre Khuri-Yakub, co-founder and Chief Scientific Officer of Orchard Ultrasound Innovation and Professor Emeritus of Electrical Engineering at Stanford University.

“我们在半导体超声领域的工作已跨越数十年，而这是我们首次以这一基础为核心，构建出一套完整的成像与治疗系统。”Orchard Ultrasound Innovation 联合创始人兼首席科学官、斯坦福大学电气工程荣休教授 Pierre Khuri-Yakub 表示。

'MaxQ is our first spinout company, and I'm proud of how far the team has taken this technology, from an idea in the lab to a platform that's ready to change how we care for men with prostate disease. I look forward to seeing it reach the patients who need it most.'.

“MaxQ 是我们的第一家衍生公司，我为团队将这项技术从实验室中的一个想法发展成为一个有望改变前列腺疾病男性患者护理模式的平台而感到自豪。我期待看到它惠及最需要的患者。”

'There's a strong need in urology for technology that allows physicians to see and treat the prostate in one setting, and we're encouraged by MaxQ's vision for treating prostate disease,' said Gabriela Kaynor, Chair of Olympus Innovation Ventures. 'We're excited to see the field develop novel technologies that can help shape and revolutionize the future of endoscopy-enabled care.'.

“泌尿外科领域对于能够让医生在同一诊疗环境中完成前列腺观察与治疗的技术有着迫切需求，我们对 MaxQ 在治疗前列腺疾病方面的愿景感到鼓舞，”奥林巴斯创新风险投资公司主席 Gabriela Kaynor 表示。“我们很高兴看到该领域不断涌现出能够塑造并彻底变革内镜辅助诊疗未来的创新技术。”

About MaxQ Medical

关于 MaxQ Medical

MaxQ Medical, Inc. is a health-tech company based in Sunnyvale, California developing a fully automated, urethra-preserving, outpatient ultrasound imaging and targeted therapy system for prostate care. The platform is designed to give urologists complete visibility of the prostate and the ability to deliver individualized treatment in a single procedure, starting with BPH and expanding into prostate cancer focal therapy and prostate diagnostics.

MaxQ Medical, Inc. 是一家总部位于加利福尼亚州桑尼维尔的健康科技公司，正在开发一种用于前列腺护理的全自动、保留尿道的门诊超声成像和靶向治疗系统。该平台旨在让泌尿科医生能够全面清晰地观察前列腺，并在单次操作中提供个性化治疗，初期专注于良性前列腺增生（BPH），并逐步拓展至前列腺癌的局灶性治疗和前列腺诊断领域。

The MaxQ System is investigational and is not currently available for commercial use in the United States. For more information visit maxqmedical.com..

MaxQ系统尚处于研究阶段，目前在美国不可用于商业用途。更多信息请访问maxqmedical.com。

About Orchard Ultrasound Innovation

关于果园超声创新

Orchard Ultrasound Innovation is a Sunnyvale, California-based company founded to commercialize breakthrough ultrasound technology developed out of Stanford University. Orchard's work builds on decades of research in semiconductor ultrasound, led by co-founder and Chief Scientific Officer Professor Pierre Khuri-Yakub, inventor of the Capacitive Micromachined Ultrasonic Transducer (CMUT).

Orchard Ultrasound Innovation 是一家总部位于加利福尼亚州森尼韦尔的公司，旨在将斯坦福大学开发的突破性超声技术商业化。Orchard 的工作建立在数十年半导体超声研究的基础之上，由联合创始人兼首席科学官皮埃尔·库里-亚库布教授领导，他是电容式微加工超声换能器（CMUT）的发明者。

The company develops and spins out ultrasound-based technology across medical and commercial applications, with MaxQ Medical as its first spinout company. For more information, visit orchardultrasound.com..

该公司开发并剥离基于超声的技术，应用于医疗和商业领域，其首家剥离公司为 MaxQ Medical。欲了解更多信息，请访问 orchardultrasound.com。

About S3 Ventures

关于 S3 Ventures

Founded in 2005, S3 Ventures is the largest and longest-serving venture capital firm born in Texas and investing nationwide. Backed by a philanthropic family with a multi-billion-dollar foundation, we empower visionary founders with the patient capital and true resources required to grow extraordinary, high-impact companies in Business Software and Healthcare Technology.

S3 Ventures 成立于2005年，是源自德克萨斯州、面向全国投资的最大且历史最悠久的风险投资公司之一。在拥有数十亿美元资产的慈善家族基金会的支持下，我们为富有远见的创始人提供所需的耐心资本和真实资源，助力他们在商业软件和医疗健康技术领域打造非凡且具有高影响力的企业。

With over $1B in assets under management, we lead Seed, Series A, and Series B rounds—with initial investments ranging from $500K to $15M and the capacity to invest $25M over the life of a company. Learn more at .

我们管理着超过10亿美元的资产，主导种子轮、A轮和B轮融资——初始投资额从50万美元到1,500万美元不等，并在一家公司的整个生命周期内具备高达2,500万美元的投资能力。了解更多请访问。

www.s3vc.com

www.s3vc.com

.

。

SOURCE MaxQ Medical, Inc

来源：MaxQ Medical, Inc.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示